164 related articles for article (PubMed ID: 35672838)
21. Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer--initial results.
Plathow C; Aschoff P; Lichy MP; Eschmann S; Hehr T; Brink I; Claussen CD; Pfannenberg C; Schlemmer HP
Invest Radiol; 2008 May; 43(5):290-7. PubMed ID: 18424949
[TBL] [Abstract][Full Text] [Related]
22. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
[TBL] [Abstract][Full Text] [Related]
23. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma.
Pfannenberg C; Aschoff P; Schanz S; Eschmann SM; Plathow C; Eigentler TK; Garbe C; Brechtel K; Vonthein R; Bares R; Claussen CD; Schlemmer HP
Eur J Cancer; 2007 Feb; 43(3):557-64. PubMed ID: 17224266
[TBL] [Abstract][Full Text] [Related]
24.
Metser U; Berlin A; Halankar J; Murphy G; Jhaveri KS; Ghai S; Tau N
AJR Am J Roentgenol; 2018 Mar; 210(3):635-640. PubMed ID: 29323548
[TBL] [Abstract][Full Text] [Related]
25. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
Hildebrandt MG; Gerke O; Baun C; Falch K; Hansen JA; Farahani ZA; Petersen H; Larsen LB; Duvnjak S; Buskevica I; Bektas S; Søe K; Jylling AM; Ewertz M; Alavi A; Høilund-Carlsen PF
J Clin Oncol; 2016 Jun; 34(16):1889-97. PubMed ID: 27001573
[TBL] [Abstract][Full Text] [Related]
26. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
[TBL] [Abstract][Full Text] [Related]
27. Small Cell Lung Cancer Staging: Prospective Comparison of Conventional Staging Tests, FDG PET/CT, Whole-Body MRI, and Coregistered FDG PET/MRI.
Ohno Y; Yoshikawa T; Takenaka D; Koyama H; Aoyagi K; Yui M; Oshima Y; Hamabuchi N; Tanaka Y; Shigemura C; Oota S; Nomura M; Murayama K; Inui Y; Kikukawa K; Toyama H
AJR Am J Roentgenol; 2022 May; 218(5):899-908. PubMed ID: 34877872
[No Abstract] [Full Text] [Related]
28. Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast.
Catalano OA; Daye D; Signore A; Iannace C; Vangel M; Luongo A; Catalano M; Filomena M; Mansi L; Soricelli A; Salvatore M; Fuin N; Catana C; Mahmood U; Rosen BR
Int J Oncol; 2017 Jul; 51(1):281-288. PubMed ID: 28535000
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.
Melsaether AN; Raad RA; Pujara AC; Ponzo FD; Pysarenko KM; Jhaveri K; Babb JS; Sigmund EE; Kim SG; Moy LA
Radiology; 2016 Oct; 281(1):193-202. PubMed ID: 27023002
[TBL] [Abstract][Full Text] [Related]
30. Whole-Body [
Berzaczy D; Fueger B; Hoeller C; Haug AR; Staudenherz A; Berzaczy G; Weber M; Mayerhoefer ME
Mol Imaging Biol; 2020 Jun; 22(3):739-744. PubMed ID: 31363965
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy.
Hansen JA; Naghavi-Behzad M; Gerke O; Baun C; Falch K; Duvnjak S; Alavi A; Høilund-Carlsen PF; Hildebrandt MG
PLoS One; 2021; 16(11):e0260066. PubMed ID: 34793550
[TBL] [Abstract][Full Text] [Related]
32. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Interobserver Agreement and Diagnostic Accuracy for IASLC/ITMIG Thymic Epithelial Tumor Staging Among Co-registered FDG-PET/MRI, Whole-body MRI, Integrated FDG-PET/CT, and Conventional Imaging Examination with and without Contrast Media Administrations.
Ohno Y; Kishida Y; Seki S; Koyama H; Yui M; Aoyagi K; Yoshikawa T
Acad Radiol; 2022 Mar; 29 Suppl 3():S122-S131. PubMed ID: 29395795
[TBL] [Abstract][Full Text] [Related]
34. [Optimization of a whole-body magnetic resonance imaging protocol for Hodgkin lymphoma staging].
Mikhaylov AI; Panov VO; Tyurin IE
Vestn Rentgenol Radiol; 2014; (6):18-28. PubMed ID: 25975129
[TBL] [Abstract][Full Text] [Related]
35. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
Zamagni E; Nanni C; Patriarca F; Englaro E; Castellucci P; Geatti O; Tosi P; Tacchetti P; Cangini D; Perrone G; Ceccolini M; Brioli A; Buttignol S; Fanin R; Salizzoni E; Baccarani M; Fanti S; Cavo M
Haematologica; 2007 Jan; 92(1):50-5. PubMed ID: 17229635
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.
Heusner TA; Kuemmel S; Koeninger A; Hamami ME; Hahn S; Quinsten A; Bockisch A; Forsting M; Lauenstein T; Antoch G; Stahl A
Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1077-86. PubMed ID: 20204355
[TBL] [Abstract][Full Text] [Related]
37. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
38. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy.
Takenaka D; Ohno Y; Matsumoto K; Aoyama N; Onishi Y; Koyama H; Nogami M; Yoshikawa T; Matsumoto S; Sugimura K
J Magn Reson Imaging; 2009 Aug; 30(2):298-308. PubMed ID: 19629984
[TBL] [Abstract][Full Text] [Related]
39. [Whole-body staging of malignant melanoma: advantages, limitations and current importance of PET-CT, whole-body MRI and PET-MRI].
Pfannenberg C; Schwenzer N
Radiologe; 2015 Feb; 55(2):120-6. PubMed ID: 25589421
[TBL] [Abstract][Full Text] [Related]
40. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
